inhibition of c3 with apl-2 in autoimmune hemolytic anemia to reduce hemolysis
Published 5 years ago • 714 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
36:31
an update on c3 glomerulopathy: understanding a rare complement-mediated kidney disease
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
0:44
b7-h6/cd3 t-cell engager bi 765049 ± ezabenlimab in advanced solid tumors expressing b7-h6
-
9:29
part ii: diabetes-friendly recipes for a nutritious breakfast
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml
-
5:20
anti-cd3 collabody™
-
1:55
assessing flt3-itd-specific mrd clearance using a pcr-ngs assay in the quantum-first trial
-
1:40
monkey apoc3 / apolipoprotein c-iii elisa kit (sku: mkfi00008) - elisa genie
-
1:44
dr. koprivnikar discusses flt3 inhibitors in hematologic malignancies
-
3:41
decoding physiology: metabolic alkalosis part 3 - gfr
-
1:06
targeting tcf3-hlf−positive all
-
3:38
the importance of cholesterol synthesis in acute demyelination
-
5:00
the adaptor mavs promotes nlrp3 mitochondrial localization and inflammasome activation
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
4:36
maintenance decitabine after intensive therapy for aml in older flt3-itd-negative patients
-
1:50
the enzyme trim3 facilitates estrogen signaling and modulates breast cancer progression
-
6:38
gilteritinib plus venetoclax for r/r flt3-mutated aml
-
5:58
the whey forward for improving postprandial glucose (nutren untuk diabetik)
-
3:22
how will the use of flt3 inhibitors evolve in the future?